Claims for Patent: 6,316,196

Summary for Patent: 6,316,196

Title:	Methods for analyzing LTC4 synthase polymorphisms and diagnostic use
Abstract:	This invention relates to single nucleotide polymorphisms in the LTC.sub.4 synthase gene, EMBL accession no. U50136, particularly at one or more of positions 375, 815, 1003, 2169 and 2742. The invention also relates to methods and materials for analyzing allelic variation in the LTC.sub.4 synthase gene, and to the use of LTC.sub.4 synthase polymorphism in tie diagnosis and treatment of leukotriene mediated diseases such as asthma and allergic rhinitis.
Inventor(s):	Morten; John Edward Norris (Macclesfield, GB)
Assignee:	Zeneca Limited (London, GB)
Application Number:	09/485,636
Patent Claims:	1. A method for detection of at least one single nucleotide polymorphism (SNP) in a human LTC.sub.4 synthase gene, which method comprises determining a nucleotide at one or more of positions 375, 815, 1003, 2169 and 2742 in the human LTC.sub.4 synthase gene as defined by the positions in SEQ ID NO: 1, and thereby detecting absence or presence of at least one SNP. 2. A method according to claim 1 in which the single nucleotide polymorphism at position 375 is presence of G and/or A. 3. A method according to claim 1 in which the single nucleotide polymorphism at position 815 is presence of C and/or A. 4. A method according to claim 1 in which the single nucleotide polymorphism at position 1003 is presence of A and/or C. 5. A method according to claim 1 in which the single nucleotide polymorphism at position 2169 is presence of C and/or T. 6. A method according to claim 1 in which the single nucleotide polymorphism at position 2742 is presence of C and/or T. 7. A method according to any one of claims 1-6 in which the sequence is determined by a method selected from amplification refractory mutation system and restriction fragment length polymorphism. 8. An isolated and purified nucleic acid comprising the 5' untranslated region of the LTC.sub.4 synthase gene comprising a polymorphism at one or more of positions 375, 815 and 1003 as defined by the positions in SEQ ID NO: 1 and in which there is an A at position 375, an A at position 815 and a C at position 1003. 9. An isolated and purified nucleic acid comprising the first intron of the LTC.sub.4 synthase gene comprising a polymorphism at one or more of positions 2169 and 2742 as defined by the position in SEQ ID NO: 1 and in which there is a T at position 2169 and there is a T at position 2742. 10. An allele-specific nucleic acid primer of 17-35 nucloetides which specifically hybridizes to and detects a LTC.sub.4 synthase gene polymorphism at one or more of positions 375, 815, 1003, 2169 and 2742 in the LTC.sub.4 synthase gene as defined by the positions in SEQ ID NO: 1. 11. An isolated and purified allele-specific oligonucleotide probe of 17-35 nucleotides which specifically hybridizes to and detects a LTC.sub.4 synthase gene polymorphism at one or more of positions 375, 815, 1003, 2169 and 2742 in the LTC.sub.4 synthase gene as defined by the positions in SEQ ID NO: 1. 12. A diagnostic kit comprising a diagnostic primer as defined in claim 10 and/or an allele-specific oligonucleotide primer as defined in claim 11.

Details for Patent 6,316,196

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2017-08-22
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2017-08-22
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2017-08-22